News

How Does Eucrisa Work? Eucrisa is a brand-name form of the generic medication crisaborole. Doctors prescribe it in topical form to help manage mild to moderate eczema.
In December, Eucrisa became the first PDE-4 blocker approved to treat mild-to-moderate eczema for people ages 2 and older. Pfizer declined to comment on the campaign.
During the drugmaker’s third-quarter earnings call with investors, Pfizer CEO Ian Read attributed growing sales of eczema drug Eucrisa to the launch of two DTC campaigns. The most recent campaign, ...
Pfizer (PFE) gets FDA approval for label expansion of Eucrisa to include children aged three months to two years with mild-to-moderate atopic dermatitis or eczema.
The FDA approval for the expanded indication of EUCRISA was supported by data from a Phase 4, open-label, clinical study.
The study was put on hold to solve stability issues in the original JW-100 formulation. These issues were addressed and resolved to the satisfaction of the study's clinical investigators.
Expected to Complete Patient Enrollment of Clinical Trial in December 2022JUPITER, FL / ACCESSWIRE / November 10, 2022 / Jupiter Wellness, Inc. (Nasdaq:JUPW), a wellness company focused on hair ...